Characteristics of Main Drug Therapy Types in Subjects With Atrial Fibrillation in Population

Malyutina, Sofia; Shapkina, Marina; Ryabikov, Andrey; Маздорова, Е. В.; Avdeeva, Ekaterina; Щербакова, Л. В.; Bobák, Martin; Hubacek, Jaroslav A.; Nikitin, Yury

doi:10.15829/1728-8800-2018-1-43-48

Cited by 2 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the Russian DM Register, in 2017, the number of people who reached the level of HbA1c < 7.0% was 52.2% [ 20 ], which was higher, compared with our study, according to the other criterion of FGP < 7 mmol/L.…”

Section: Discussioncontrasting

confidence: 81%

“…Early findings on drug therapy for atrial fibrillation, antihypertensive and lipid-lowering therapy in the studied population have previously been reported [ 20 , 21 , 22 ]. The present paper continues a systematic series of works on the pharmacotherapy of cardiometabolic diseases in the modern Russian population, using a population-based urban sample of older age persons in Novosibirsk.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Profile of Glucose Lowering Therapy in Persons with Type 2 Diabetes Mellitus in an Aging Russian Population

Malyutina

Mazurenko

Маздорова

et al. 2022

JPM

View full text Add to dashboard Cite

We aimed to analyze the profile of glucose lowering therapy (GLT) in persons with diabetes mellitus type 2 (DM2) in an aging Russian population. A random population sample (n = 3898, men/women, 55–84) was examined in Novosibirsk, during 2015–2018 (HAPIEE Project). The design of the present work is a cross-sectional study. DM2 was defined in those with a history of DM2 receiving GLT, or at a level of fasting plasma glucose (FPG) ≥7.0 mmol/L. The entire DM2 group was included in the analysis (n = 803); of these, 476 persons were taking GLT and were included in the analysis at stage 2. Regular GLT medication intake for 12 months was coded with ATC. In studied sample, the prevalence of DM2 was 20.8%. Among subjects with DM2, 59% of individuals received GLT, 32% did not. Glycemic control (FPG < 7.0 mmol/L) was achieved in every fifth participant with DM2 (35% in those receiving GLT). In frequency of GLT use, biguanides ranked in first place (75%), sulfonylurea derivatives in second (35%), insulins in third (12%), and iDPP-4 in fourth (5%). Among those receiving GLT, 24% used combined oral therapy, and 6% used insulin-combined therapy. In conclusion, in a population sample aged 55–84 examined in 2015–2018, glycemic control was achieved in every fifth participant with DM2, and in every third participant receiving GLT. The proportion of participants using new GLT drugs was small, and there was a lack of HbA1c monitoring for intensive glycemic control.

show abstract

Section: Discussioncontrasting

confidence: 81%

Section: Introductionmentioning

confidence: 99%

The Profile of Glucose Lowering Therapy in Persons with Type 2 Diabetes Mellitus in an Aging Russian Population

Malyutina

Mazurenko

Маздорова

et al. 2022

JPM

View full text Add to dashboard Cite

show abstract

“…Настоящая статья продолжает системную серию работ по изучению профиля фармакотерапии кардиометаболических заболеваний (КМЗ) в современной российской популяции на примере популяционной городской выборки Новосибирска [29,30].…”

Section: автор для перепискиunclassified

The frequency and profile of drug treatment in subjects with dyslipidemias and cardimetabolic diseases in an urban russian population older then 55 years

et al. 2021

Self Cite

View full text Add to dashboard Cite

Aim To analyze frequency and profile of the lipid-lowering therapy (LLT) in patients with dyslipidemia (DLP) and cardiometabolic diseases (CMD) in a population sample aged 55-84 years at the current time (2015–2017).Material and methods Despite guidelines on DLP treatment and the availability of effective and safe lipid-lowering drugs, control of DPL in primary and secondary prevention of cardiovascular diseases (CVD) is insufficient. Knowledge of the level of pharmaceutical correction of DLP in the Russian population is limited; it requires an LLT assessment in various regions and in a wide age range, and a regular monitoring taking into account changing approaches to the correction of DLP. A random population of men and women aged 55–84 years (n=3 896) was evaluated in Novosibirsk in 2015–2017 (project HAPIEE). A joint DLP category was established as low-density lipoprotein cholesterol (LDL-C) ≥3.0 mmol/l, or total cholesterol (TC) ≥5.0 mmol/l, or triglycerides (TG) ≥1.7 mmol/l, or LLT. The combined group of DLP and CMD included ischemic heart disease (IHD), type 2 diabetes mellitus (DM2), and DLP. Regular LLD treatment for the recent 12 months, excluding the dosage of medicines, was assessed using the Anatomic Therapeutic Chemical (ATC) classification. The conditional control of serum lipids was taken as the achievement of LDL-C <3.0 mmol/l, TC <5.0 mmol/l, and TG <1.7 mmol/l.Results In the study sample, the total prevalence of DLP and CMD was 88 % (82.8 % for men and 91.3 % for women, p<0.001). 48.3% of patients in the IHD group, 35.0% in the DM2 group, 29.4% in the DLP group, and 32.8% in the CMD group took LLT. Control of serum lipids was achieved in 18.3% (37.9 % of patients on LLT) of patients with IHD; 9 % (25.6 % of patients on LLT) of patients with DM2; 7.3 % (24.8 % of patients on LLT) of patients with DLP; and 9.0 % (27.6 % of patients on LLTсреди) in the DLP and CMD group. Women with DM2 and DLP more frequently achieved lipid control than men (p<0.001). 98.7 % of study participants took statins as LLT.Conclusion In the sample of urban population aged 55–84 years in 2015–2017, 90 % of patients had DLP or CMD, and at least ¾ of them required blood lipid control. The lipid control was achieved in every fifth IHD patient and in approximately 40% of those who took LLT. For DM2 or DLP patients, the lipid control was achieved in every tenth patient and in approximately 25% of those receiving LLT. Frequency of lipid control in IHD patients was comparable for men and women; in DM2 and DLP, men less frequently achieved the lipid control than women. About 70% of patients in the combined DLP and CMD group and more than 50% of IHD patients did not take LLT, which considerably contributed to the insufficient lipid control in primary and secondary prevention of atherosclerotic CVDs in this population.

show abstract

Characteristics of Main Drug Therapy Types in Subjects With Atrial Fibrillation in Population

Cited by 2 publications

References 11 publications

The Profile of Glucose Lowering Therapy in Persons with Type 2 Diabetes Mellitus in an Aging Russian Population

The Profile of Glucose Lowering Therapy in Persons with Type 2 Diabetes Mellitus in an Aging Russian Population

The frequency and profile of drug treatment in subjects with dyslipidemias and cardimetabolic diseases in an urban russian population older then 55 years

Contact Info

Product

Resources

About